ArticleBMC pharmacology & toxicology2025

Commentary on "real world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies".

Ali Beheshti Namdar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.